期刊文献+

稳定表达人CCR5基因CHO细胞系的建立及鉴定 被引量:1

Establishment and characterization of CHO cell line stably expressing human CCR5 gene
下载PDF
导出
摘要 CC型趋化因子受体5(CCR5)是HIV-1感染机体所需的最重要的辅助受体和潜在的抗病毒药物靶点之一.将含有人CCR5基因的真核表达质粒pcDNA3.1-CCR5稳定转染CHO-K1细胞,G418筛选2周后,在96孔板内通过有限稀释法培养细胞单克隆,最后得到22个细胞克隆,用流式细胞术检测细胞表面CCR5蛋白,发现克隆10能够高表达人CCR5基因.使用RT-PCR鉴定克隆10CCR5基因转录情况,结果在预期的位置检测出目的条带.采用细胞ELISA的方法进一步鉴定克隆10细胞表面CCR5的表达,结果该克隆的405nm光密度值是对照组的13.6倍.结果表明,本研究建立的稳定转染人CCR5的CHO细胞系能够高效表达CCR5基因,为研究HIV-1共受体、筛选病毒中和抗体、以及抗病毒药物奠定了基础. CCR5 is one of the most important co-receptors required for HIV-I infection and a potential target for anti viral agents. In this study,the eukaryotic expression plasmid pcDNA3.1 CCR5 carrying human CCR5 gene was stably transfected into CHO-K1 cells. After 2 weeks selection by G418, cell clones were selected from limited dilution in 96-well plates,and 22 clones were obtained. All the clones were analyzed for cell surface CCR5 expression using flow cytometry, and clone 10 was identified as a high expression clone. The CCR5 gene transcription of the clone 10 was further analyzed using RT PCR and gel electrophoresis,and the target band was visible in the expected location. Cellular ELISA indicated that the surface CCR5 expression of clone 10 was 13. 6 fold higher than the control cells. Our results indicated that the CHO cell line stably expressing human CCR5 can be a useful tool for study viral co receptor,specific antibody screening and anti-viral agents.
出处 《南京大学学报(自然科学版)》 CAS CSCD 北大核心 2012年第6期804-808,共5页 Journal of Nanjing University(Natural Science)
基金 国家自然科学基金(30870124) 科技部国际合作项目(2009DFA31260)
关键词 CC型趋化因子受体5 稳定转染 细胞酶联免疫吸附实验 人类免疫缺陷病毒 CC chernokine receptor type 5, stably transfection,cellular ELISA,human immunodeficiency virus
  • 相关文献

参考文献17

  • 1Owens M A, Vail H G, Hurley A D,et al. Validationand quality control of immunophenotyping in clinicalflow cytometry. Journal of Immunological Methods,2000,243(1—2):33-50.
  • 2Alkhatib G,Combadiere C,Broder C C,C al. CCCKR5 : A RANTES,MIP-lalpha,MIP-lbetareceptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 1996,272:1955-1958.
  • 3Farber J M,Berger E A. HIV's response to aCCR5 inhibitor: I’d rather tighten than switch!Proceedings of the National Academy of Sciencesof the United States of America, 2002 ,99 ( 4):1749 -1751.
  • 4Gilliam B L’Riedel D J ,Redfield R R. Clinical useof CCR5 inhibitors in HIV and beyond. Journal ofTranslational Medicine,2011,9(Suppl 1) :S9.
  • 5Allers K,Hutter G,Hofmann J , et al. Evidencefor the cure of HIV infection by CCR5 A32/A32stem cell transplantation. Blood,2011,117(10):2791-2799.
  • 6Li L, Sun T, Yang K, et al. Monoclonal CCR5antibody for treatment of people with HIVinfection. Cochrane Database of SystematicReviews,2010,8(12) :CD008439.
  • 7Latinovic O, Reitz M,Le N, et al. CCR5 antibodiesHGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity ofMaraviroc-resivstant HIV-1 in primary cells.Virology,2011,411 (1): 32 -40.
  • 8Bodiwala H S,Sabde S,Gupta P.et al. Design andsynthesis of caffeoyl-anilides as portmanteauinhibitors of HIV-1 integrase and CCR5. Bioorganic Medicinal Chemistry, 2011,19(3):1256-1263.
  • 9Da L T, Wu Y D. Theoretical studies on theinteractions and interferences of HIV-1 glycoproteingpl20 and its coreceptor CCR5. Journal of ChemicalInformation and Modeling,2011 ,51(2) :359-369.
  • 10Schanzer J,Jekle A, Nezu J , et al. Development oftetravalent, bispecific CCR5 antibodies with antiviralactivity against CCR5 monoclonal antibody-resistantHIV-1 strains. Antimicrobial Agents andChemotherapy,2011,55(5):2369-2378.

同被引文献9

  • 1Cornu TI,Mussolino C,Bloom K,et al.Editing CCR5:A Novel Approach to HIV Gene Therapy[J].AdvExp Med Biol,2015,8(9947):117-130.
  • 2Lopalco L.Natural anti-CCR5antibodies in HIV-infection andexposure[J].J Transl Med,2011,27(9):1-11.
  • 3Stoddart CA,Galkina SA,Joshi P,et al.Efficacy of broadly neutralizing monoclonal antibody PG16in HIV-infected humanized mice[J].Virology,2014,462(463):115-125.
  • 4Liu S,Kong C,Wu J,et al.Effect of CCR5-Δ32heterozygosity on HIV-1susceptibility:a meta-analysis[J].PLoS One,2012,7(4):1-6.
  • 5Jin J,Colin P,Staropoli I,et al.Targeting spare CC chemokine receptor 5(CCR5)as a principle to inhibit HIV-1entry[J].J BiolChem,2014,289(27):19042-19052.
  • 6Latinovic O,Reitz M,Le N,et al.CCR5antibodies HGS004and HGS101preferentially inhibit drug bound CCR5infection and restore drug sensitivity of Maraviroc-resistant HIV-1in primary cells[J].Virology,2011,411(1):32-40.
  • 7Da LT,Wu YD.Theoretical studies on the interactions and interferences of HIV-1glycoprotein gp120and its coreceptor CCR5[J].J ChemInf Model,2011,51(2):359-369.
  • 8Dogo-Isonagie C,Lam S,Gustchina E,et al.Peptides from second extracellular loop of C-C chemokine receptor type 5(CCR5)inhibit diverse strains of HIV-1[J].J BiolChem,2012,287(18):15076-15086.
  • 9NCAIDS,NCSTD,China CDC.2015年1月全国艾滋病性病疫情及主要防治工作进展[J].中国艾滋病性病,2015,21(3):175-175. 被引量:17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部